Martijn J Wilmer
Overview
Explore the profile of Martijn J Wilmer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
832
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Keuper-Navis M, Walles M, Poller B, Myszczyszyn A, van der Made T, Donkers J, et al.
Pharmacol Res
. 2023 Jul;
195:106853.
PMID: 37473876
Organ-on-chip (OoC) technology has led to in vitro models with many new possibilities compared to conventional in vitro and in vivo models. In this review, the potential of OoC models...
2.
Vormann M, Vriend J, Lanz H, Gijzen L, van den Heuvel A, Hutter S, et al.
J Pharm Sci
. 2021 Feb;
110(4):1601-1614.
PMID: 33545187
Proximal tubule epithelial cells (PTEC) are susceptible to drug-induced kidney injury (DIKI). Cell-based, two-dimensional (2D) in vitro PTEC models are often poor predictors of DIKI, probably due to the lack...
3.
Janssen M, Nieskens T, Steevels T, Caetano-Pinto P, den Braanker D, Mulder M, et al.
Mol Ther Nucleic Acids
. 2019 Oct;
18:298-307.
PMID: 31610379
Antisense oligonucleotide therapy has been reported to be associated with renal injury. Here, the mechanism of reversible proteinuria was investigated by combining clinical, pre-clinical, and in vitro data. Urine samples...
4.
Vriend J, Peters J, Nieskens T, Skovronova R, Blaimschein N, Schmidts M, et al.
Biochim Biophys Acta Gen Subj
. 2019 Sep;
1864(1):129433.
PMID: 31520681
Background: Kidney disease modeling and assessment of drug-induced kidney injury can be advanced using three-dimensional (3D) microfluidic models that recapitulate in vivo characteristics. Fluid shear stress (FSS) has been depicted...
5.
Vriend J, Hoogstraten C, Venrooij K, van den Berge B, Govers L, van Rooij A, et al.
Biol Chem
. 2019 Jan;
400(10):1347-1358.
PMID: 30653465
Organic anion transporters (OATs) 1 and 3 are, besides being uptake transporters, key in several cellular metabolic pathways. The underlying mechanisms are largely unknown. Hence, we used human conditionally immortalized...
6.
Sjogren A, Breitholtz K, Ahlberg E, Milton L, Forsgard M, Persson M, et al.
Arch Toxicol
. 2018 Aug;
92(10):3175-3190.
PMID: 30155723
Drug-induced nephrotoxicity is a major concern in the clinic and hampers the use of available treatments as well as the development of innovative medicines. It is typically discovered late during...
7.
Vriend J, Nieskens T, Vormann M, van den Berge B, van den Heuvel A, Russel F, et al.
AAPS J
. 2018 Jul;
20(5):87.
PMID: 30051196
Drug-transporter interactions could impact renal drug clearance and should ideally be detected in early stages of drug development to avoid toxicity-related withdrawals in later stages. This requires reliable and robust...
8.
Fedecostante M, Westphal K, Buono M, Sanchez Romero N, Wilmer M, Kerkering J, et al.
Drug Metab Dispos
. 2018 Jul;
46(9):1338-1350.
PMID: 29980578
Drug-induced kidney injury in medicinal compound development accounts for over 20% of clinical trial failures and involves damage to different nephron segments, mostly the proximal tubule. Yet, currently applied cell...
9.
Nieskens T, Peters J, Dabaghie D, Korte D, Jansen K, Van Asbeck A, et al.
Drug Metab Dispos
. 2018 Mar;
46(5):592-599.
PMID: 29514829
Cisplatin is a cytostatic drug used for treatment of solid organ tumors. The main adverse effect is organic cation transporter 2 (OCT2)-mediated nephrotoxicity, observed in 30% of patients. The contribution...
10.
Mihajlovic M, Van den Heuvel L, Hoenderop J, Jansen J, Wilmer M, Westheim A, et al.
Sci Rep
. 2017 Aug;
7(1):7103.
PMID: 28769101
Novel renal replacement therapies, such as a bioartificial kidney (BAK), are needed to improve current hemodialysis treatment of end-stage renal disease (ESRD) patients. As BAK applications may reveal safety concerns,...